Infos pour
Accès direct
UFR
Helena Loer
Forschungsgebiet
|
Lebenslauf
Seit 12/2021: Doktorandin in der Klinischen Pharmazie und Externe Doktorandin im Graduate Research Training Program „PharMetrX - Pharmacometrics & Computational Disease Modelling“
04/2021 – 11/2021: Masterandin in der Klinischen Pharmazie, Universität des Saarlandes, Saarbrücken
01/2021: Approbation als Apothekerin
05/2020 – 10/2020: Praktisches Jahr, Schloss Apotheke, Bergisch Gladbach
11/2019 – 04/2020: Praktisches Jahr, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß
10/2015 – 09/2019: Studium der Pharmazie, Rheinische Friedrich-Wilhelms-Universität, Bonn
07/2014 – 07/2015: Freiwilliges Soziales Jahr, Tansania
06/2014: Abitur, Friedrich-Wilhelm-Gymnasium, Köln
Publikationen
Manuskripte
Kovar C, Loer HLH, Rüdesheim S, Fuhr LM, Marok FZ, Selzer D, Schwab M, Lehr T. A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions. CPT Pharmacometrics Syst Pharmacol. 2024. doi:10.1002/psp4.13146 Loer HLH, Kovar C, Rüdesheim S, Marok FZ, Fuhr LM, Selzer D, Schwab M, Lehr T. Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions. CPT Pharmacometrics Syst Pharmacol. 2024;00:1-15. Feick D, Rüdesheim S, Marok FZ, Selzer D, Loer HLH, Teutonico D, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Schwab M, Lehr T. Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug–drug–gene interaction network. CPT Pharmacometrics Syst Pharmacol 2023;00:1-14. Loer HLH, Feick D, Rüdesheim S, Selzer D, Schwab M, Teutonico D, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Lehr T. Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions. CPT Pharmacometrics Syst Pharmacol 2023;00:1-15. Loer HLH, Türk D, Gómez-Mantilla JD, Selzer D, Lehr T. Physiologically based pharmakokinetic (PBPK) modeling of clopidogrel and its four relevant metabolites for CYP2B6, CYP2C8, CYP2C19 and CYP3A4 drug-drug-gene interaction predictions. Pharmaceutics 2022;14(5):915. |
Poster
Loer HLH, Kovar C, Schwab M, Lehr T. Physiologically based pharmacokinetic modeling of imatinib and its main metabolite for drug-drug interaction predictions. 31st Population Approach Group Europe (PAGE) meeting, 2023, A Coruña, Spain. Loer HLH, Feick D, Lehr T. Physiologically based pharmacokinetic (PBPK) modeling of tacrolimus for CYP3A drug-drug-gene interaction predictions. Annual Meeting of the German Pharmaceutical Society (DPhG), 2022, Marburg, Germany. Loer HLH, Türk D, Selzer D, Lehr T. Dose adaptations for drug-gene and drug-drug interactions involving clopidogrel – A physiologically based pharmacokinetic (PBPK) modeling approach. 30th Population Approach Group Europe (PAGE) meeting, 2022, Ljubljana, Slovenia. |
Kontakt
Helena Loer Klinische Pharmazie T: +49/681/302-70254 |